Kura Oncology Inc. (NASDAQ:KURA)’s share price shot up 5.4% on Thursday . The company traded as high as $2.77 and last traded at $2.74, with a volume of 77,425 shares. The stock had previously closed at $2.60.

A number of research firms recently weighed in on KURA. Oppenheimer Holdings Inc. reaffirmed an “outperform” rating and set a $16.00 price objective on shares of Kura Oncology in a research report on Tuesday, June 21st. Zacks Investment Research cut shares of Kura Oncology from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Citigroup Inc. lowered their price objective on shares of Kura Oncology from $19.00 to $12.00 and set a “buy” rating for the company in a research report on Monday, March 21st.

The company’s 50-day moving average is $2.89 and its 200 day moving average is $4.04. The firm’s market capitalization is $53.29 million.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Wednesday, May 11th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by $0.01. Equities analysts forecast that Kura Oncology Inc. will post ($1.70) earnings per share for the current fiscal year.

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.